logo
Plus   Neg
Share
Email

Sanofi, Regeneron Offer Praluent At 60% Reduced U.S. List Price - Quick Facts

French drug giant Sanofi SA (SNYNF,SNY) said Monday that Praluent or alirocumab, will be made available at a new reduced U.S. list price of $5,850 annually, a 60 percent reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March.

Praluent or alirocumab Injection inhibits the binding of PCSK9 or proprotein convertase subtilisin/kexin type 9 to the LDL receptor and thereby increases the number of available LDL receptors on the surface of liver cells to clear LDL, which lowers LDL-C levels in the blood. Praluent was developed by Regeneron Pharmaceuticals (REGN) and Sanofi under a global collaboration agreement.

The new lower-priced Praluent is expected to result in lower patient out-of-pocket costs, and represents another step in the companies' efforts to help improve patient affordability and access.

This follows an earlier announcement in March 2018, when Sanofi and Regeneron committed to lower the U.S. net price for payers in return for helping to reduce burdensome access barriers for appropriate patients.

"We were encouraged to see improvements in accessibility following our collaboration with payers last year to provide more straightforward, affordable access to Praluent, but only some patients had reduced out-of-pocket costs. With today's announcement, we are looking to help bridge that gap, and have now made Praluent available at a price that is approximately 60% lower," said Michelle Carnahan, North America Head of Primary Care Business Unit at Sanofi.

The new, lower-priced Praluent is expected to be available for pharmacies to order in early March, and the doses with the original list price will remain on the market at least through 2019. The lower-priced Praluent will be identical to the Praluent currently available, other than the list price.

With the new lower-priced Praluent, most Medicare Part D patients are expected to pay between $25 to $150 per month, a potential savings of up to $345, depending on their insurance plan. Eligible commercial patients will continue to have access to co-pay assistance through MyPraluent, Sanofi said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter, Honeywell international Inc. (HON) on Thursday raised its earnings and sales outlook for the full-year 2019. For fiscal 2019, the company raised its earnings outlook to a range of $7.90 to $8.15 per share from the previous guidance range of... Chipmaker Intel Corp. said it plans to exit the 5G smartphone modem business, with the announcement coming just hours after Apple Inc. and Qualcomm Inc. said they have settled their royalty dispute. The settlement includes a payment from Apple to Qualcomm, but no details were disclosed about the payment or fees. Qualcomm's shares are gaining more than 14 percent in Wednesday's trading session. Snack and beverage giant PepsiCo Inc. (PEP) on Wednesday reported an increase in net income for the first quarter, reflecting higher revenues. Both adjusted earnings per share and net revenues for the quarter beat analysts' estimates. The company also reaffirmed its earnings and organic revenue growth outlook for the full-year 2019.
Follow RTT